Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ben Tran

Showing results (161-170 of 170) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 170 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2026
Safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy from a first-in-human study of volrustomig, a novel PD-1/CTLA-4 bispecific antibodyBen Tran, Mark Voskoboynik, Sang-We Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2024
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate CancerTanya Dorff, Lisa G Horvath, Karen Autio, et al.
NPJ Precision Oncology|May 7, 2026
A roadmap for establishing institutional readiness for cellular therapies targeting solid tumours and autoimmune diseasesSarah Childs, David Ma, Elizabeth Houghton, et al.
The Oncologist|October 6, 2025
Guiding first-line treatment decisions in advanced urothelial carcinoma: a global surveyEnrique Grande, Joaquim Bellmunt, Syed A Hussain, et al.
Ebiomedicine|October 17, 2021
Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinaseHui-Ming Lin, Blossom Mak, Nicole Yeung, et al.
Gut|February 9, 2018
Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker studyJeanne Tie, Joshua D Cohen, Yuxuan Wang, et al.
The Lancet. Oncology|July 5, 2025
First-in-human results of terbium-161 [<sup>161</sup>Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 studyJames P Buteau, Louise Kostos, Price A Jackson, et al.
Cancer Discovery|January 9, 2021
Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1<sup>+</sup> Activated T CellsSimon J Dovedi, Matthew J Elder, Chunning Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2021
Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update ConsortiumJörg Beyer, Laurence Collette, Nicolas Sauvé, et al.
Journal for Immunotherapy of Cancer|February 15, 2019
Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)Sneha Berry, Nicolas Giraldo, Peter Nguyen, et al.
Pageof 17

Showing results (161-170 of 170) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 170 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2026
Safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy from a first-in-human study of volrustomig, a novel PD-1/CTLA-4 bispecific antibodyBen Tran, Mark Voskoboynik, Sang-We Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2024
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate CancerTanya Dorff, Lisa G Horvath, Karen Autio, et al.
NPJ Precision Oncology|May 7, 2026
A roadmap for establishing institutional readiness for cellular therapies targeting solid tumours and autoimmune diseasesSarah Childs, David Ma, Elizabeth Houghton, et al.
The Oncologist|October 6, 2025
Guiding first-line treatment decisions in advanced urothelial carcinoma: a global surveyEnrique Grande, Joaquim Bellmunt, Syed A Hussain, et al.
Ebiomedicine|October 17, 2021
Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinaseHui-Ming Lin, Blossom Mak, Nicole Yeung, et al.
Gut|February 9, 2018
Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker studyJeanne Tie, Joshua D Cohen, Yuxuan Wang, et al.
The Lancet. Oncology|July 5, 2025
First-in-human results of terbium-161 [<sup>161</sup>Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 studyJames P Buteau, Louise Kostos, Price A Jackson, et al.
Cancer Discovery|January 9, 2021
Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1<sup>+</sup> Activated T CellsSimon J Dovedi, Matthew J Elder, Chunning Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2021
Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update ConsortiumJörg Beyer, Laurence Collette, Nicolas Sauvé, et al.
Journal for Immunotherapy of Cancer|February 15, 2019
Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)Sneha Berry, Nicolas Giraldo, Peter Nguyen, et al.
Pageof 17